Combined Use of cyclinD1 and Ki67 for Prognosis of Luminal-Like Breast Cancer Patients

BackgroundKi67 is a biomarker of proliferation to be used in immunohistochemistry (IHC)-based surrogate assay to determine the necessity of cytotoxic therapy for Luminal-like breast cancer patients. cyclinD1 is another frequently used biomarker of proliferation. A retrospective study was performed h...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Junmei Hao, Wenfeng Zhang, Yan Lyu, Jiarui Zou, Yunyun Zhang, Jiahong Lyu, Jianbo Zhang, Shuishan Xie, Cuiping Zhang, Jiandi Zhang, Fangrong Tang
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	QDB FFPE Ki67 Luminal-like breast cancer cyclin D1 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/7d3287aa92df48ea9ea56251068666fa
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7d3287aa92df48ea9ea56251068666fa
record_format	dspace
spelling	oai:doaj.org-article:7d3287aa92df48ea9ea56251068666fa2021-11-09T06:42:03ZCombined Use of cyclinD1 and Ki67 for Prognosis of Luminal-Like Breast Cancer Patients2234-943X10.3389/fonc.2021.737794https://doaj.org/article/7d3287aa92df48ea9ea56251068666fa2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.737794/fullhttps://doaj.org/toc/2234-943XBackgroundKi67 is a biomarker of proliferation to be used in immunohistochemistry (IHC)-based surrogate assay to determine the necessity of cytotoxic therapy for Luminal-like breast cancer patients. cyclinD1 is another frequently used biomarker of proliferation. A retrospective study was performed here to investigate if these two biomarkers may be combined to improve the prognosis of Luminal-like patients.MethodsBoth Ki67 and cyclinD1 protein levels were measured absolutely and quantitatively using Quantitative Dot Blot method in 143 Luminal-like specimens. Optimized cutoffs for these two biomarkers were developed to evaluate their prognostic roles using Kaplan–Meier overall survival (OS) analysis.ResultscyclinD1 was found as an independent prognostic factor from Ki67 in univariate and multivariate OS analyses. At optimized cutoffs (cyclinD1 at 0.44 μmol/g and Ki67 at 2.31 nmol/g), the subgroup with both biomarkers below the cutoffs (n = 65) had 10-year survival probability at 90% in comparison to those with both biomarkers above the cutoffs (n = 18) with 8-year survival probability at 26% (log-rank test, p <0.0001). This finding was used to modify the surrogate assay using IHC-based cyclinD1 scores, with p-value decreased from 0.031 to 0.00061 or from 0.1 to 0.02, when the Ki67 score of 14 or 20% was used as cutoff, respectively, in the surrogate assay.ConclusionThe current study supports the prospective investigation of cyclinD1 relevance in the clinic.Junmei HaoWenfeng ZhangYan LyuJiarui ZouYunyun ZhangJiahong LyuJianbo ZhangShuishan XieCuiping ZhangJiandi ZhangFangrong TangFrontiers Media S.A.articleQDBFFPEKi67Luminal-likebreast cancercyclin D1Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	QDB FFPE Ki67 Luminal-like breast cancer cyclin D1 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	QDB FFPE Ki67 Luminal-like breast cancer cyclin D1 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Junmei Hao Wenfeng Zhang Yan Lyu Jiarui Zou Yunyun Zhang Jiahong Lyu Jianbo Zhang Shuishan Xie Cuiping Zhang Jiandi Zhang Fangrong Tang Combined Use of cyclinD1 and Ki67 for Prognosis of Luminal-Like Breast Cancer Patients
description	BackgroundKi67 is a biomarker of proliferation to be used in immunohistochemistry (IHC)-based surrogate assay to determine the necessity of cytotoxic therapy for Luminal-like breast cancer patients. cyclinD1 is another frequently used biomarker of proliferation. A retrospective study was performed here to investigate if these two biomarkers may be combined to improve the prognosis of Luminal-like patients.MethodsBoth Ki67 and cyclinD1 protein levels were measured absolutely and quantitatively using Quantitative Dot Blot method in 143 Luminal-like specimens. Optimized cutoffs for these two biomarkers were developed to evaluate their prognostic roles using Kaplan–Meier overall survival (OS) analysis.ResultscyclinD1 was found as an independent prognostic factor from Ki67 in univariate and multivariate OS analyses. At optimized cutoffs (cyclinD1 at 0.44 μmol/g and Ki67 at 2.31 nmol/g), the subgroup with both biomarkers below the cutoffs (n = 65) had 10-year survival probability at 90% in comparison to those with both biomarkers above the cutoffs (n = 18) with 8-year survival probability at 26% (log-rank test, p <0.0001). This finding was used to modify the surrogate assay using IHC-based cyclinD1 scores, with p-value decreased from 0.031 to 0.00061 or from 0.1 to 0.02, when the Ki67 score of 14 or 20% was used as cutoff, respectively, in the surrogate assay.ConclusionThe current study supports the prospective investigation of cyclinD1 relevance in the clinic.
format	article
author	Junmei Hao Wenfeng Zhang Yan Lyu Jiarui Zou Yunyun Zhang Jiahong Lyu Jianbo Zhang Shuishan Xie Cuiping Zhang Jiandi Zhang Fangrong Tang
author_facet	Junmei Hao Wenfeng Zhang Yan Lyu Jiarui Zou Yunyun Zhang Jiahong Lyu Jianbo Zhang Shuishan Xie Cuiping Zhang Jiandi Zhang Fangrong Tang
author_sort	Junmei Hao
title	Combined Use of cyclinD1 and Ki67 for Prognosis of Luminal-Like Breast Cancer Patients
title_short	Combined Use of cyclinD1 and Ki67 for Prognosis of Luminal-Like Breast Cancer Patients
title_full	Combined Use of cyclinD1 and Ki67 for Prognosis of Luminal-Like Breast Cancer Patients
title_fullStr	Combined Use of cyclinD1 and Ki67 for Prognosis of Luminal-Like Breast Cancer Patients
title_full_unstemmed	Combined Use of cyclinD1 and Ki67 for Prognosis of Luminal-Like Breast Cancer Patients
title_sort	combined use of cyclind1 and ki67 for prognosis of luminal-like breast cancer patients
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/7d3287aa92df48ea9ea56251068666fa
work_keys_str_mv	AT junmeihao combineduseofcyclind1andki67forprognosisofluminallikebreastcancerpatients AT wenfengzhang combineduseofcyclind1andki67forprognosisofluminallikebreastcancerpatients AT yanlyu combineduseofcyclind1andki67forprognosisofluminallikebreastcancerpatients AT jiaruizou combineduseofcyclind1andki67forprognosisofluminallikebreastcancerpatients AT yunyunzhang combineduseofcyclind1andki67forprognosisofluminallikebreastcancerpatients AT jiahonglyu combineduseofcyclind1andki67forprognosisofluminallikebreastcancerpatients AT jianbozhang combineduseofcyclind1andki67forprognosisofluminallikebreastcancerpatients AT shuishanxie combineduseofcyclind1andki67forprognosisofluminallikebreastcancerpatients AT cuipingzhang combineduseofcyclind1andki67forprognosisofluminallikebreastcancerpatients AT jiandizhang combineduseofcyclind1andki67forprognosisofluminallikebreastcancerpatients AT fangrongtang combineduseofcyclind1andki67forprognosisofluminallikebreastcancerpatients
_version_	1718441211917762560

Combined Use of cyclinD1 and Ki67 for Prognosis of Luminal-Like Breast Cancer Patients

Ejemplares similares